All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): STP938
Therapeutic Area: Oncology Product Name: STP938
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Hadean Ventures
Deal Size: $42.3 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 23, 2021
Details:
The proceeds will be used to advance Step Pharma’s lead proprietary CTPS1 inhibitor, STP938, into clinical development for the treatment of T-cell malignancies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hafnium dioxide,Undisclosed
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2021
Details:
The combination therapy of NBTXR3 + XRT + anti-PD-1 + anti-LAG3 + anti-TIGIT (Combo therapy) significantly promoted the proliferation activity of CD8+ T cells, improved local and distant tumor control, and increased survival rate.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NK-001,Bispecific antibody
Therapeutic Area: Oncology Product Name: NK-001
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Onward Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 17, 2021
Details:
Onward will assist EMERCell to scale up their patented process of activation and amplification of allogeneic NK cells which includes one of EMERCell's lead drug candidates, NK-001 and to conduct clinical investigations.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bispecific antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Onward Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 16, 2021
Details:
Biomunex grants the rights for Onward to pursue development, manufacture and commercialization of this first-in-class bispecific antibody. Onward and Biomunex will jointly develop the antibody during the preclinical and early clinical program.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CYT-150
Therapeutic Area: Oncology Product Name: CYT-150
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cytovia Therapeutics
Deal Size: $775.0 million Upfront Cash: $15.0 million
Deal Type: Partnership February 16, 2021
Details:
Cellectis will develop custom TALEN®, which Cytovia will use to edit iPSCs. Cytovia will look after differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and will conduct the pre-clinical evaluation, clinical development activities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BMX-101
Therapeutic Area: Oncology Product Name: BMX-101
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Onward Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
